Literature DB >> 12943746

Urinary equol excretion in relation to 2-hydroxyestrone and 16alpha-hydroxyestrone concentrations: an observational study of young to middle-aged women.

Charlotte Atkinson1, Heather E Skor, E Dawn Fitzgibbons, Delia Scholes, Chu Chen, Kristiina Wähälä, Stephen M Schwartz, Johanna W Lampe.   

Abstract

Approximately one-third to one-half of individuals harbor the colonic bacteria that are capable of metabolizing the soy isoflavone daidzein to equol. Results of prior studies suggest beneficial effects of producing equol in relation to breast cancer risk, potentially through effects on endogenous hormones. High urinary excretion of 2-hydroxyestrone (2-OH E(1)) relative to 16alpha-hydroxyestrone (16alpha-OH E(1)) has been associated with a reduced risk of breast cancer. In this pilot study we examined associations between urinary excretion of equol and 2-OH E(1), 16alpha-OH E(1), and their ratio, and investigated whether excretion of these estrogen metabolites differed between two samples collected 48h apart. Isoflavones (genistein, daidzein, O-desmethylangolensin (ODMA), and equol) were measured in two overnight urines from 126 women. Excretion of 2-OH E(1) and 16alpha-OH E(1) were measured in the first overnight urine from all 126 women and in the second overnight urine from 30 of these women; there were no significant differences between samples collected 48h apart in excretion of 2-OH E(1) or 16alpha-OH E(1) (P=0.75 and 0.17, respectively). Among all women, correlations between total isoflavone excretion (sum of genistein, daidzein, ODMA, and equol) and estrogen metabolites were non-significant (P>0.05). Among women with detectable levels of equol, total isoflavone excretion was significantly positively correlated with 16alpha-OH E(1) (r=0.32, P=0.02), but was not correlated with 2-OH E(1) or 2-OH E(1):16alpha-OH E(1) ratio (r=0.21, P=0.14, and r=-0.05, P=0.70, respectively). Equol excretion (adjusted for other isoflavone excretion) was significantly positively correlated with 2-OH E(1):16alpha-OH E(1) ratio (r=0.38, P=0.005), but was not correlated with 2-OH E(1) or 16alpha-OH E(1) (r=0.15, P=0.29, and r=-0.17, P=0.24, respectively). The finding that equol excretion, but not total isoflavone excretion, correlated positively with the 2-OH E(1):16alpha-OH E(1) ratio suggests that the colonic bacterial profile associated with equol production may be involved in estrogen metabolism, and may therefore possibly influence breast cancer risk.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12943746     DOI: 10.1016/s0960-0760(03)00259-0

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  6 in total

Review 1.  Does equol production determine soy endocrine effects?

Authors:  Dana Shor; Thozhukat Sathyapalan; Stephen L Atkin; Natalie J Thatcher
Journal:  Eur J Nutr       Date:  2012-02-25       Impact factor: 5.614

Review 2.  Gut microbes, diet, and cancer.

Authors:  Meredith A J Hullar; Andrea N Burnett-Hartman; Johanna W Lampe
Journal:  Cancer Treat Res       Date:  2014

3.  S-(-)equol producing status not associated with breast cancer risk among low isoflavone-consuming US postmenopausal women undergoing a physician-recommended breast biopsy.

Authors:  Mandeep K Virk-Baker; Stephen Barnes; Helen Krontiras; Tim R Nagy
Journal:  Nutr Res       Date:  2013-12-18       Impact factor: 3.315

4.  Urinary estrogen metabolites in two soy trials with premenopausal women.

Authors:  G Maskarinec; Y Morimoto; S Heak; M Isaki; A Steinbrecher; L Custer; A A Franke
Journal:  Eur J Clin Nutr       Date:  2012-06-20       Impact factor: 4.016

5.  Soy consumption during menopause.

Authors:  S Bolca; M Bracke; H Depypere
Journal:  Facts Views Vis Obgyn       Date:  2012

6.  Impact of Short-Term Isoflavone Intervention in Polycystic Ovary Syndrome (PCOS) Patients on Microbiota Composition and Metagenomics.

Authors:  Christoph Haudum; Lisa Lindheim; Angelo Ascani; Christian Trummer; Angela Horvath; Julia Münzker; Barbara Obermayer-Pietsch
Journal:  Nutrients       Date:  2020-06-01       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.